Published in AIDS Weekly, May 10th, 2004
Instead, Fuzeon sales are below estimates and analysts are slashing revenue projections. Fuzeon's $20,000-a-year price tag, painful side effects and changing AIDS treatment strategies have made sales a disappointment, one that some experts expect will continue.
Hoffmann-La Roche Inc. which markets Fuzeon for the drug's developer, Durham, North Carolina-based Trimeris Inc., is taking steps to increase sales, expanding distribution and launching an advertising...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.